Comparative Pharmacology
Head-to-head clinical analysis: TARACTAN versus THORAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: TARACTAN versus THORAZINE.
TARACTAN vs THORAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Thioxanthene antipsychotic; blocks postsynaptic dopamine D1 and D2 receptors in the mesolimbic system; also has anticholinergic, antihistaminergic, and alpha-adrenergic blocking effects.
Antagonist at dopamine D2 receptors in the mesolimbic pathway; also blocks alpha-adrenergic, histaminergic, and muscarinic receptors.
Oral: 25-50 mg three times daily, increased as needed to 400-600 mg/day. IM: 12.5-25 mg every 6-8 hours.
10-25 mg orally 3-4 times daily; maximum 800 mg/day. 25-50 mg intramuscularly every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 20-40 hours (mean 30 hours). Steady-state reached in 5-7 days.
Terminal elimination half-life: 15–30 hours (mean ~24 h); may extend to 40+ h in elderly or hepatic impairment.
Primarily hepatic metabolism; <1% excreted unchanged in urine. Metabolites eliminated renally (30%) and fecally (70%).
Renal (biliary/fecal): ~70% renal as metabolites, ~30% biliary/fecal; <1% unchanged in urine.
Category C
Category C
Typical Antipsychotic
Typical Antipsychotic